On July 15, 2022 Libera Bio reported that it has closed its Seed Round to advance its MPN Technology into enabling studies and towards the clinic (Press release, Libera Bio, JUL 15, 2022, View Source [SID1234616703]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Antibodies delivered via the MPN Technology are proven in vivo to bind with intracellular cancer targets and shrink tumors, in preclinical studies
Co-developing two antibodies against different KRAS mutations with a top ten pharma
Establishing alliances with companies designing novel monoclonal antibodies to deliver them intracellularly using Libera’s MPN Technology
Closing its EUR 1.3 million Seed Round